Figure 6.

CXCL10 deletion dampens PD-1 blockade efficacy. (A). Schematic diagram of the protocol for the anti-PD-1 treatment of tumor-bearing mice. C57BL/6 and Cxcl10^−/− mice were subcutaneously inoculated with 2 × 10⁶ MC38 tumor cells, then injected i.p. with 200 μg of anti-PD-1 antibody or isotype control antibody on days 4, 7, 10, and 13 after tumor cell inoculation. Tumor growth was monitored until the experimental endpoints. (B). Tumor growth in C57BL/6 and Cxcl10^−/− mice treated with control or anti-PD-1 antibody. Six mice were in each group. (C). Flow cytometry analysis followed by quantification of CD45⁺ cells, CD4⁺TILs, CD8⁺TILs, and Foxp3⁺Treg within tumors of C57BL/6 and Cxcl10^−/− mice treated with control or anti-PD-1 antibodies (n = 6). (D). Representative flow cytometry plots and quantitation of the percentages of IFN-γ expression in CD8⁺TILs (n = 6). Data are presented as the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 according to the one-way ANOVA test and the log-rank test.